Resources Repository
-
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Probability/Bayes | Test Performance | Health/Medicine | Technology Assessment | Infectious Diseases | Health Systems | Policy/Regulation | Government/Law | Global | North America -
EditorialPublication 2018Combining A4R and MCDA in Priority Setting for Health
Multiple criteria decision analysis (MCDA) has been proposed as a method for determining the criteria …
Multiple criteria decision analysis (MCDA) has been proposed as a method for determining the criteria to be used in health technology assessment. A standard criticism of MCDA is that it lacks attention to securing legitimacy for its decisions. Accountability for reasonableness (A4R) proposes four conditions (publicity, relevance, revisability and enforcement) that must be met if legitimacy and fairness are to be ascribed to decisions about priority setting.The relevance condition of A4R has been criticized for…
Priority Setting/Ethics | Preferences/Values | Health/Medicine -
EditorialPublication 2023Societal Perspective: Themed Issue on Productivity Costs, Consumption Costs, Informal Care Costs
Economic evaluations in healthcare assess the costs and benefits of new interventions, particularly pharmaceuticals, to …
Economic evaluations in healthcare assess the costs and benefits of new interventions, particularly pharmaceuticals, to inform funding and reimbursement decisions. These evaluations compare a new intervention against a relevant comparator, with the relevance of costs and benefits depending on the chosen perspective. The healthcare perspective, which assumes a fixed budget and aims to maximize health outcomes, considers only health impacts and costs within the budget. This approach simplifies the evaluation but may lead to suboptimal…
Costing Methods | Health/Medicine | Cost-Effectiveness Analysis